- Home
- PLX vs SGMT Comparison
PLX vs SGMT Comparison
Compare PLX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLX | SGMT |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.4M | 169.4M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLX | SGMT |
|---|---|---|
| Price | $2.37 | $7.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.00 | ★ $26.13 |
| AVG Volume (30 Days) | 641.2K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,744,000.00 | $2,000,000.00 |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $4.50 |
| 52 Week High | $3.19 | $11.41 |
Technical Indicators
Market Signals| Indicator | PLX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 64.79 | 52.37 |
| Support Level | $2.06 | $7.09 |
| Resistance Level | $2.42 | $7.39 |
| Average True Range (ATR) | 0.10 | 0.43 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 83.38 | 52.14 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.